Aptar, a drug delivery systems company, has announced the next phase of its capacity expansion plan in North America, focusing on its Congers, New York site. 

This investment aims to address the increasing demand for proprietary drug delivery systems in both prescription and consumer healthcare markets across North America, benefiting local customers.

Since its inception in 2002, the Aptar Congers site has been at the forefront of manufacturing Aptar Pharma's VP3 pumps. Today, it manufactures a diverse range of proprietary drug delivery products for nasal and injectable routes. With this expansion, the facility will further enhance its manufacturing capabilities to offer innovative solutions and increased production capacity to Aptar Pharma customers in the region.

Key components of the expansion include:

Expanded Production for Unidose Nasal Spray Systems: Aptar Pharma is significantly increasing the manufacturing capacity of its Unidose Nasal Spray Systems to meet the rising demand for systemic nasal delivery. This expansion involves the addition of molds and assembly lines in cleanroom settings, with the new capacity expected to be operational by Q4 2024.

Initiation of Bag-on-Valve Assembly: Aptar Pharma is installing an assembly line at the Congers facility to meet the growing demand for nasal saline solutions. This environmentally controlled production area, slated for completion by early 2025, will enhance manufacturing of the company's bag-on-valve technology.

Expansion of Child-Resistant Senior-Friendly Solutions: In response to increasing demand for child-resistant packaging for nasal decongestant sprays, Aptar Pharma is extending its CRSF closure solutions production at the Congers site. This includes a cleanroom extension to increase manufacturing capacity and supply customers locally.

The new capacity, housed in a building extension at the existing Congers site, is expected to be completed by the end of 2024. This expansion aligns with Aptar Pharma's global expansion plan and supports the company's "local for local" strategy to meet regional customer needs effectively.

Gael Touya, President of Aptar Pharma, highlighted the significance of the expansion in meeting customer demands. “This expansion is a key step in the next phase of our global expansion program, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients,” Touya said.